I agree with you here. For memory Dr Grossman did say early on things were going to plan. But, common sense here, we know it's a complex trial and regardless the spike in cases. Rem_l is for patients on ventilators and the difficult part is convincing them to participate on trial.
investors can argue the company needs to inform shareholders of current situation.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-707
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |